IL17A and obesity disorder: WGPHs not only reduced PBMCs proliferation but also decreased the production of IFN-γ and IL-17 cytokines, two key mediators involved in many inflammatory conditions, such as obesity, diabetes, inflammatory bowel disease and CD [18,19].